Small Cell Lung Cancer News

News

Palliative Care Needs in Patients With Small Cell Lung Cancer and Caregivers: Survey Insights

10/16/2024

A study presented at the 2024 ASCO Quality Care Symposium highlights gaps in palliative care access and education for patients with small cell lung cancer and their caregivers, emphasizing the urgent need for improved outreach and support in...

A study presented at the 2024...

10/16/2024

Journal of Clinical Pathways

Conference Coverage

Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

12/13/2022

Katie Herman ;

Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.

Jennifer R Brown and colleagues...

12/13/2022

Journal of Clinical Pathways

News

Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC

12/22/2021

Janelle Bradley ;

Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.

Adding durvalumab to etoposide...

12/22/2021

Journal of Clinical Pathways

News

Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC

12/03/2021

Marta Rybczynski ;

Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.

Results from a real-world study...

12/03/2021

Journal of Clinical Pathways

News

Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years

10/22/2021

Marta Rybczynski ;

Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.

Study findings suggest that...

10/22/2021

Journal of Clinical Pathways

News

Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC

09/07/2021

A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.

A recent study revealed that...

09/07/2021

Journal of Clinical Pathways

News

Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC

09/01/2021

Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.

Study findings suggest...

09/01/2021

Journal of Clinical Pathways

News

Cost-Effectiveness of First-Line Chemo-Immunotherapy for Extensive-Stage SCLC

08/05/2021

Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...

Study findings suggest...

08/05/2021

Journal of Clinical Pathways

News

Nivolumab vs Standard of Care for Third-Line Treatment of SCLC

08/04/2021

Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.

Study findings show third-line...

08/04/2021

Journal of Clinical Pathways

News

Real-World Treatment Patterns and Outcomes Among Patients With SCLC

07/22/2021

A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.

A recent systematic review on...

07/22/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Small Cell Lung Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products